Sahoo Dibyajyoti, Karnesh Sunil Jai, Abhishekh B
Department of Transfusion Medicine, JIPMER (Jawaharlal Institute of Postgraduate Medical Education and Research), Puducherry, India.
Indian J Hematol Blood Transfus. 2024 Jul;40(3):443-447. doi: 10.1007/s12288-023-01716-4. Epub 2023 Dec 16.
India achieved impressive strides by providing 1.7 billion doses of the COVID-19 vaccine to more than 940 million people, attaining 100% first dose coverage and 80% overall immunization coverage as of February 9, 2022. Compared to unvaccinated individuals, vaccinated people have considerably decreased risks of infection, serious illness, hospitalization, and death. With the help of this study, we determined the prevalence of COVID-19 IgG antibodies with respect to vaccination. The cross-sectional analytical study was conducted from July 2021 to April 2022 on 809 healthy donors. All donor samples were screened for COVID-19 IgG antibodies against S1 protein using IgG ELISA kits (Qualisa COVID-19 IgG kits, Tulip, Goa, India). Data regarding COVID-19 infection history, vaccination status, type of vaccine, and the number of doses were obtained. All data were entered in Microsoft Excel and analyzed using SPSS version 21. Out of 809 blood donors, a total of 650 participants were vaccinated, among which 89.5% had COVID-19 IgG antibodies and 10.5% had no antibodies. Out of the 159 who had not taken vaccination, 52.8% of the participants had COVID-19 IgG antibodies, and 47.2% of the donors had no COVID-19 IgG antibodies. A total of 617 participants have taken the Covishield vaccine, of which 90.2% had COVID-19 IgG antibodies. A total of 32 donors have taken Covaxin, of which 78.1% had COVID-19 IgG antibodies. The above study has shown that COVID-19 vaccination enhances covid antibody formation, and multiple doses of vaccine ensure longevity of these antibodies.
印度通过为超过9.4亿人提供17亿剂新冠疫苗取得了令人瞩目的进展，截至2022年2月9日，首剂接种覆盖率达到100%，总体免疫覆盖率达到80%。与未接种疫苗的个体相比，接种疫苗的人感染、重症、住院和死亡风险大幅降低。借助这项研究，我们确定了新冠病毒免疫球蛋白G（IgG）抗体与疫苗接种相关的流行情况。2021年7月至2022年4月对809名健康献血者进行了横断面分析研究。使用IgG酶联免疫吸附测定试剂盒（Qualisa新冠病毒IgG试剂盒，印度果阿郁金香公司）对所有献血者样本进行新冠病毒针对刺突蛋白1（S1）的IgG抗体筛查。获取了有关新冠病毒感染史、疫苗接种状况、疫苗类型和接种剂量的数据。所有数据录入微软Excel并使用SPSS 21版进行分析。在809名献血者中，共有650名参与者接种了疫苗，其中89.5%有新冠病毒IgG抗体，10.5%没有抗体。在159名未接种疫苗的人中，52.8%的参与者有新冠病毒IgG抗体，47.2%的献血者没有新冠病毒IgG抗体。共有617名参与者接种了阿斯利康疫苗，其中90.2%有新冠病毒IgG抗体。共有32名献血者接种了科维福疫苗，其中78.1%有新冠病毒IgG抗体。上述研究表明，新冠疫苗接种可增强新冠抗体形成，多剂疫苗可确保这些抗体的持久性。
